ASCO Launches Online Educational Initiative: ‘Grand Rounds’

Publication
Article
OncologyONCOLOGY Vol 14 No 7
Volume 14
Issue 7

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource-ASCO Grand Rounds- for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource—ASCO Grand Rounds— for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will be conducted by leading oncologists and cancer-care professionals and will include a physician-moderated online question-and-answer session for ASCO members. This new resource is available from ASCO OnLine, at www.asco.org.

Staying Current

ASCO Grand Rounds offers physicians an easy way to stay abreast of developments in cancer research. Each lecture consists of a 20- to 45-minute discussion that participants can listen to while viewing a synchronized slide presentation. Lectures will cover topics such as new drug development, cancer genetics, and supportive care and will be available throughout the year on ASCO’s website. Approximately two new lectures will be presented each month.

“We are excited that ASCO is taking a leading role in providing online education to oncologists around the world,” said ASCO president Joseph S. Bailes, MD.

Articles in this issue
Non–Small-Cell Lung Cancer Single-Agent Therapy
Linezolid-A New Option for Treating Gram-Positive Infections
Current Issues in the Treatment of Resistant Bloodstream Infections
Current Treatments for Infection in Neutropenic Patients With Hematologic Malignancy
Changing Patterns of Infections and Antimicrobial Susceptibilities
Ambulatory Antimicrobial Therapy for Hematologic Malignancies
Questions and Answers: Non–Small-Cell Lung Cancer
Questions and Answers: Small-Cell Lung Cancer
Irinotecan in Small-Cell Lung Cancer-Japanese Trials
Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC
Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
Extensive Small-Cell Lung Cancer: A Treatment Overview
Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Recent Videos
4 experts in this video
4 experts in this video
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.